Mike has focused to educate shareholders about angiography and contrast induced kidney injury and how renal cells in diabetic patients are more prone to injury, instead of giving useful information about the challenges that the company is dealing with, about how the company is looking to expand its portfolio and the market, how the company is going to cut the expenses, how the R$D is spending about $500 quarterly and what the fruit has been.
Mike, at least please let the shareholders know about the next scheduled 1:100 consolidation.
- Forums
- ASX - By Stock
- OSP
- Ann: CEO Investor Presentation
Ann: CEO Investor Presentation, page-17
-
- There are more pages in this discussion • 97 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)